BACKGROUND: ACY1215 is a selective histone deacetylase 6 (HDAC6) inhibitor, and can suppress tumor growth for many human cancers. However, its role in colon cancer and its impact on the chemotherapeutic effect of 5-fluorouracil (5-Fu) are largely unknown. The aim of the present study is to explore the effect of ACY1215 on cell growth, migration, invasion and apoptosis, along with its impact on the chemotherapeutic effect of 5-Fu in HCT116 cells. METHODS: HCT116 cells were treated with ACY1215 with or without 5-Fu, and cell viability, proliferation, migration, invasion and apoptosis were explored. RESULTS: The cell viability, colony formation number, wound closure rate, and migrated cell numbers of HCT116 cells significantly decreased, while the apoptotic cells significantly increased with the increased concentration of ACY1215 (P<0.05). The combination of ACY1215 and 5-Fu was more potent than either drug alone, as indicated by an increase of apoptotic cells, and by a decrease of cell viability, colony formation number, wound closure rate and migrated cell numbers. The expression of phosphorylated mitogen-activated protein kinases (pMEK) and phosphorylated extracellular-signal regulated protein kinase (pERK) were decreased when HCT116 cells were cultured with ACY1215. CONCLUSIONS: Selective HDAC6 inhibitor, ACY1215, could inhibit the cell proliferation, migration and invasion, and induce apoptosis of HCT116 colon cancer cells. Furthermore, ACY1215 may enhance the chemotherapeutic effect of 5-Fu in HCT116 cells.
BACKGROUND: ACY1215 is a selective histone deacetylase 6 (HDAC6) inhibitor, and can suppress tumor growth for many human cancers. However, its role in colon cancer and its impact on the chemotherapeutic effect of 5-fluorouracil (5-Fu) are largely unknown. The aim of the present study is to explore the effect of ACY1215 on cell growth, migration, invasion and apoptosis, along with its impact on the chemotherapeutic effect of 5-Fu in HCT116 cells. METHODS: HCT116 cells were treated with ACY1215 with or without 5-Fu, and cell viability, proliferation, migration, invasion and apoptosis were explored. RESULTS: The cell viability, colony formation number, wound closure rate, and migrated cell numbers of HCT116 cells significantly decreased, while the apoptotic cells significantly increased with the increased concentration of ACY1215 (P<0.05). The combination of ACY1215 and 5-Fu was more potent than either drug alone, as indicated by an increase of apoptotic cells, and by a decrease of cell viability, colony formation number, wound closure rate and migrated cell numbers. The expression of phosphorylated mitogen-activated protein kinases (pMEK) and phosphorylated extracellular-signal regulated protein kinase (pERK) were decreased when HCT116 cells were cultured with ACY1215. CONCLUSIONS: Selective HDAC6 inhibitor, ACY1215, could inhibit the cell proliferation, migration and invasion, and induce apoptosis of HCT116 colon cancer cells. Furthermore, ACY1215 may enhance the chemotherapeutic effect of 5-Fu in HCT116 cells.
Authors: A Saito; T Yamashita; Y Mariko; Y Nosaka; K Tsuchiya; T Ando; T Suzuki; T Tsuruo; O Nakanishi Journal: Proc Natl Acad Sci U S A Date: 1999-04-13 Impact factor: 11.205
Authors: Anthony Tumber; Laura S Collins; Kamille Dumong Petersen; Annemette Thougaard; Sanne J Christiansen; Marielle Dejligbjerg; Peter Buhl Jensen; Maxwell Sehested; James W A Ritchie Journal: Cancer Chemother Pharmacol Date: 2006-11-24 Impact factor: 3.333
Authors: Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544
Authors: William Fazzone; Peter M Wilson; Melissa J Labonte; Heinz-Josef Lenz; Robert D Ladner Journal: Int J Cancer Date: 2009-07-15 Impact factor: 7.396
Authors: Janine Arts; Peter King; Ann Mariën; Wim Floren; Ann Beliën; Lut Janssen; Isabelle Pilatte; Bruno Roux; Laurence Decrane; Ron Gilissen; Ian Hickson; Veronique Vreys; Eugene Cox; Kees Bol; Willem Talloen; Ilse Goris; Luc Andries; Marc Du Jardin; Michel Janicot; Martin Page; Kristof van Emelen; Patrick Angibaud Journal: Clin Cancer Res Date: 2009-10-27 Impact factor: 12.531
Authors: Richard L Piekarz; Robin Frye; Maria Turner; John J Wright; Steven L Allen; Mark H Kirschbaum; Jasmine Zain; H Miles Prince; John P Leonard; Larisa J Geskin; Craig Reeder; David Joske; William D Figg; Erin R Gardner; Seth M Steinberg; Elaine S Jaffe; Maryalice Stetler-Stevenson; Stephen Lade; A Tito Fojo; Susan E Bates Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544
Authors: Yu Zhang; Sohee Kwon; Teppei Yamaguchi; Fabien Cubizolles; Sophie Rousseaux; Michaela Kneissel; Chun Cao; Na Li; Hwei-Ling Cheng; Katrin Chua; David Lombard; Adam Mizeracki; Gabriele Matthias; Frederick W Alt; Saadi Khochbin; Patrick Matthias Journal: Mol Cell Biol Date: 2008-01-07 Impact factor: 4.272
Authors: Alejandro Urdiciain; Elena Erausquin; María V Zelaya; Idoya Zazpe; José L Lanciego; Bárbara Meléndez; Juan A Rey; Miguel A Idoate; Natalia A Riobo-Del Galdo; Javier S Castresana Journal: Biology (Basel) Date: 2021-05-26